Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy-Reference-Cited by-同舟云学术

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Published:2021-06-16 Issue:4 Volume:8 Page:497-508
ISSN:2199-1154
Container-title:Drugs - Real World Outcomes
language:en
Short-container-title:Drugs - Real World Outcomes

Author:

Freeman Leorah^ORCID,Kee Arianna,Tian Marc,Mehta Rina

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40801-021-00251-w.pdf

Reference27 articles.

1. Nicholas JA, Edwards NC, Edwards RA, Dellarole A, Grosso M, Phillips AL. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurol. 2020;20(1):281.

2. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009;277(Suppl 1):S42–5.

3. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029–40.

4. Hunter SF. Overview and diagnosis of multiple sclerosis. Am J Manag Care. 2016;22(Suppl 6):S141–50.

5. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008;255(2):280–7.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-09

2. Influence of time to ablation on outcomes among patients with atrial fibrillation with pre-existing heart failure;Heart Rhythm O2;2024-08

3. Differential gene expression in B cells and T helper cells following high-dose glucocorticoid therapy for multiple sclerosis relapse;Biomedicine & Pharmacotherapy;2024-06

4. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-05

5. Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis;Brain and Behavior;2024-04-30